Marieke van Son

96 CHAPTER 5 Table 2 – Univariable Cox regression analysis for biochemical failure Risk factor β HR 95% CI p-value lower upper Age AJCC grade group* Group 2 (3+4=7) Group 3 (4+3=7) Group 4 (4+4=8) Group 5 (9/10) MRI T-stage** ≥T3 PSA PSADT Size of the CTV (cc) -0.06 0.24 0.77 -0.8 0.81 0.95 0.06 -0.02 0.05 0.94 1.27 2.16 0.45 2.24 2.6 1.1 0.98 1.1 0.87 0.36 0.64 0.05 0.56 1.17 1 0.95 1 1 4.5 7.24 4.03 9.06 5.78 1.1 1 1.1 0.16 0.71 0.21 0.48 0.26 0.02 0.02 0.2 0.04 β: estimate of the effect, HR: hazard ratio, 95% CI: 95% confidence interval, AJCC: American joint committee on cancer, PSA: prostate specific antigen level, PSADT: PSA doubling time, CTV: clinical target volume. *AJCC grade group 1 (3+3=6) as reference category. **MRI stage T2 as reference category. Figure 4 – Kaplan Meier BDFS survival curves stratified for low (stage<T3 and PSA<10 and PSADT>9 months) and high risk of treatment failure (anyone else).